Target Price | GBP142.80 |
Price | GBP104.02 |
Potential | 37.28% |
Number of Estimates | 29 |
29 Analysts have issued a price target AstraZeneca 2026 . The average AstraZeneca target price is GBP142.80. This is 37.28% higher than the current stock price. The highest price target is GBP182.70 75.64% , the lowest is GBP68.65 34.01% . | |
A rating was issued by 35 analysts: 29 Analysts recommend AstraZeneca to buy, 6 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the AstraZeneca stock has an average upside potential 2026 of 37.28% . Most analysts recommend the AstraZeneca stock at Purchase. |
31 Analysts have issued a sales forecast AstraZeneca 2025 . The average AstraZeneca sales estimate is GBP43.1b . This is 7.75% higher than the revenue of the last 12 months(TTM). The highest sales forecast is GBP45.5b 13.63% , the lowest is GBP38.4b 4.11% .
This results in the following potential growth metrics:
2024 | GBP39.4b | 18.03% |
---|---|---|
2025 | GBP43.1b | 9.56% |
2026 | GBP45.8b | 6.09% |
2027 | GBP48.4b | 5.77% |
2028 | GBP50.6b | 4.55% |
2029 | GBP54.1b | 6.97% |
2030 | GBP58.8b | 8.61% |
2031 | GBP61.4b | 4.45% |
2032 | GBP61.7b | 0.42% |
26 Analysts have issued an AstraZeneca EBITDA forecast 2025. The average AstraZeneca EBITDA estimate is GBP15.7b . This is 25.93% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is GBP19.7b 57.84% , the lowest is GBP11.8b 5.31% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | GBP12.1b | 29.46% |
---|---|---|
2025 | GBP15.7b | 30.18% |
2026 | GBP17.3b | 10.39% |
2027 | GBP18.8b | 8.79% |
2028 | GBP19.9b | 5.57% |
2029 | GBP22.7b | 13.91% |
2030 | GBP26.7b | 17.78% |
2031 | GBP28.7b | 7.70% |
2032 | GBP29.3b | 1.90% |
2024 | 30.60% | 9.68% |
---|---|---|
2025 | 36.36% | 18.81% |
2026 | 37.84% | 4.07% |
2027 | 38.92% | 2.85% |
2028 | 39.30% | 0.98% |
2029 | 41.85% | 6.49% |
2030 | 45.38% | 8.43% |
2031 | 46.80% | 3.13% |
2032 | 47.49% | 1.47% |
28 AstraZeneca Analysts have issued a net profit forecast 2025. The average AstraZeneca net profit estimate is GBP10.4b . This is 84.24% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is GBP11.7b 106.55% , the lowest is GBP8.4b 49.26% .
This results in the following potential growth metrics and future Net Margins:
2024 | GBP5.1b | 18.14% |
---|---|---|
2025 | GBP10.4b | 103.54% |
2026 | GBP11.8b | 13.40% |
2027 | GBP13.0b | 9.77% |
2028 | GBP14.1b | 8.66% |
2029 | GBP15.9b | 12.50% |
2030 | GBP17.4b | 9.81% |
2031 | GBP16.0b | 8.08% |
2032 | GBP15.0b | 6.32% |
2024 | 13.01% | 0.09% |
---|---|---|
2025 | 24.17% | 85.78% |
2026 | 25.84% | 6.91% |
2027 | 26.81% | 3.75% |
2028 | 27.87% | 3.95% |
2029 | 29.31% | 5.17% |
2030 | 29.63% | 1.09% |
2031 | 26.08% | 11.98% |
2032 | 24.33% | 6.71% |
28 Analysts have issued a AstraZeneca forecast for earnings per share. The average AstraZeneca EPS is GBP6.73 . This is 85.40% higher than earnings per share in the financial year 2024. The highest EPS forecast is GBP7.54 107.71% , the lowest is GBP5.45 50.14% .
This results in the following potential growth metrics and future valuations:
2024 | GBP3.28 | 18.41% |
---|---|---|
2025 | GBP6.73 | 105.18% |
2026 | GBP7.63 | 13.37% |
2027 | GBP8.37 | 9.70% |
2028 | GBP9.10 | 8.72% |
2029 | GBP10.23 | 12.42% |
2030 | GBP11.24 | 9.87% |
2031 | GBP10.33 | 8.10% |
2032 | GBP9.68 | 6.29% |
Current | 27.88 | 30.21% |
---|---|---|
2025 | 15.05 | 46.02% |
2026 | 13.27 | 11.83% |
2027 | 12.09 | 8.89% |
2028 | 11.13 | 7.94% |
2029 | 9.89 | 11.14% |
2030 | 9.01 | 8.90% |
2031 | 9.80 | 8.77% |
2032 | 10.46 | 6.73% |
Based on analysts' sales estimates for 2025, the AstraZeneca stock is valued at an EV/Sales of 4.12 and an P/S ratio of 3.67 .
This results in the following potential growth metrics and future valuations:
Current | 4.44 | 26.12% |
---|---|---|
2025 | 4.12 | 7.26% |
2026 | 3.88 | 5.74% |
2027 | 3.67 | 5.45% |
2028 | 3.51 | 4.35% |
2029 | 3.28 | 6.52% |
2030 | 3.02 | 7.92% |
2031 | 2.89 | 4.26% |
2032 | 2.88 | 0.42% |
Current | 3.96 | 27.33% |
---|---|---|
2025 | 3.67 | 7.19% |
2026 | 3.46 | 5.74% |
2027 | 3.27 | 5.45% |
2028 | 3.13 | 4.35% |
2029 | 2.93 | 6.52% |
2030 | 2.70 | 7.92% |
2031 | 2.58 | 4.26% |
2032 | 2.57 | 0.41% |
Analyst | Rating | Action | Date |
---|---|---|---|
Berenberg Bank |
➜
Buy
|
Unchanged | May 16 2025 |
Shore Capital |
➜
Buy
|
Unchanged | Apr 29 2025 |
Berenberg Bank |
➜
Buy
|
Unchanged | Mar 26 2025 |
Shore Capital |
➜
Buy
|
Unchanged | Mar 07 2025 |
JP Morgan Cazenove |
➜
Overweight
|
Unchanged | Feb 19 2025 |
Berenberg Bank |
➜
Buy
|
Unchanged | Jan 27 2025 |
Berenberg Bank |
➜
Buy
|
Unchanged | Jan 06 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Berenberg Bank:
➜
Buy
|
May 16 2025 |
Unchanged
Shore Capital:
➜
Buy
|
Apr 29 2025 |
Unchanged
Berenberg Bank:
➜
Buy
|
Mar 26 2025 |
Unchanged
Shore Capital:
➜
Buy
|
Mar 07 2025 |
Unchanged
JP Morgan Cazenove:
➜
Overweight
|
Feb 19 2025 |
Unchanged
Berenberg Bank:
➜
Buy
|
Jan 27 2025 |
Unchanged
Berenberg Bank:
➜
Buy
|
Jan 06 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.